Novel B-RAF-Inhibitor Cream Ameliorates Rash From EGFR Inhibitors
An investigational novel cream containing a BRAF inhibitor appears to ameliorate the acneiform rash associated with epidermal growth factor receptor (EGFR) inhibitors such as cetuximab (Erbitux) and panitumumab (Vectibix).
The results come from a first-in-human, phase 1 clinical trial conducted in 10 patients with metastatic colorectal cancer who were receiving treatment with either cetuximab or panitumumab and who developed a grade 1 or grade 2 rash while on treatment.
All were treated with the novel topical cream, dubbed LUTO14 (under development by Lutris Pharmaceutical).